NCT00294320

Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions

Pilot Study to Evaluate Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions (Clinical and Sub-clinical), When Treated With Aldara 5% (Imiquimod) Cream

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: MEDA Pharma GmbH & Co. KG · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the performance of two techniques to monitor the clearance of AK lesions when treated with Aldara 5% cream.

Detailed description

Each technique will be assessed by comparison of lesion counts (clinical and sub-clinical) revealed by the techniques, at start and end of the study and those demonstrated during treatment. In addition a qualitative assessment of each technique will be made for performance and ease of use.

Conditions

• Actinic Keratosis

Interventions

Type	Name	Description
DRUG	Aldara (Imiquimod)	250mg of Imiquimod cream for application once daily 3 times per week.
OTHER	Vehicle cream	250mg vehicle cream for application once daily 3 times per week.

Timeline

• Start date: 2006-02-01
• Primary completion: 2007-01-01
• Completion: 2007-01-01
• First posted: 2006-02-22
• Last updated: 2022-02-07

Locations

1 site across 1 country: France